MetaVia Inc. Files 2024 10-K, Details Financials
Ticker: MTVA · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 10-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals, corporate-history
Related Tickers: MTVA
TL;DR
MetaVia (MTVA) filed its 2024 10-K. Shows financials, past names: NeuroBo, Gemphire. #Pharma
AI Summary
MetaVia Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations as a pharmaceutical preparations company. The filing details financial positions including retained earnings and additional paid-in capital for the years 2022, 2023, and 2024. MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., with its last name change occurring on December 31, 2019.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of MetaVia Inc.'s financial health and historical corporate changes, crucial for understanding its current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, MetaVia Inc. faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for the 10-K)
- 2023 — Fiscal Year End (Prior reporting period)
- 2022 — Fiscal Year End (Prior reporting period)
Key Players & Entities
- MetaVia Inc. (company) — Filer of the 10-K
- NeuroBo Pharmaceuticals, Inc. (company) — Former name of MetaVia Inc.
- Gemphire Therapeutics Inc. (company) — Former name of MetaVia Inc.
- 2024-12-31 (date) — Fiscal year end
- 2023-12-31 (date) — Prior fiscal year end
- 2022-12-31 (date) — Prior fiscal year end
FAQ
What is the primary business of MetaVia Inc.?
MetaVia Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
When did MetaVia Inc. change its name from NeuroBo Pharmaceuticals, Inc.?
The date of the name change from NeuroBo Pharmaceuticals, Inc. to MetaVia Inc. was December 31, 2019.
What are the key financial components reported for the fiscal year ending December 31, 2024?
The filing reports on us-gaap:RetainedEarningsMember and us-gaap:AdditionalPaidInCapitalMember for the fiscal year ending December 31, 2024.
What was MetaVia Inc.'s former name prior to being NeuroBo Pharmaceuticals, Inc.?
Prior to being NeuroBo Pharmaceuticals, Inc., MetaVia Inc. was formerly known as Gemphire Therapeutics Inc.
What is the business address of MetaVia Inc.?
The business address for MetaVia Inc. is 545 Concord Avenue, Suite 210, Cambridge, MA 02138.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding MetaVia Inc. (MTVA).